Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Purchase Of Schering AG Would Give Firm Focus On Specialty Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

$19. 5 bil. offer by Bayer will likely thwart hostile takeover of Schering by Merck KgaA.
Advertisement

Related Content

Bayer Benefits From Diversification, Despite Flat Pharma Growth in 2010
Bayer Benefits From Diversification, Despite Flat Pharma Growth in 2010
Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward
Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward
Bayer Shops For More Schering AG Shares Outside Of Takeover Bid
Bayer Continues Schering Takeover Bid After Rival Merck Bolsters Holdings
Berlex’ YAZ Clears FDA For Contraception; April Launch Planned
Merck KgaA Unsolicited Bid For Schering AG Would Create $13.4 Bil. Firm
Merck KgaA Unsolicited Bid For Schering AG Would Create $13.4 Bil. Firm
"Bayer-ly" An Rx Company? Viadur Is Focus Of New Bayer Oncology Unit

Topics

Advertisement
UsernamePublicRestriction

Register

PS063896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel